A look at the LC and LC–MS methods that are helping to overcome challenges in sample analysis, and how this can make adeno‑associated virus (AAV)–based gene therapy more accessible.
Recombinant adeno-associated viral therapy (rAAV) products are particularly complex. Are liquid chromatography and LC–MS the right tools for their characterization?